1 / 4

CAR T Cell Therapy Market Size, Growth | Industry Report, 2020-2026

The global CAR T cell therapy market size is anticipated to expand at a substantial CAGR during the forecast period, 2020 u2013 2026. Additionally, the report offers latest trends, size, share, and industry overview<br>

KeenCatPost
Download Presentation

CAR T Cell Therapy Market Size, Growth | Industry Report, 2020-2026

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Welcome To DataIntelo CAR T Cell Therapy Market Size, Growth | Industry Report, 2020-2026 The global CAR T cell therapy market size is anticipated to expand at a substantial CAGR during the forecast period, 2020 – 2026 owing to factors such as rising prevalence of cancer worldwide, technological advancements for reliable cancer treatments, and booming pharmaceutical industry. The demand for chimeric antigen receptor (CAR) T cell therapy has increased for the treatment of cancer. The therapy is an innovative immunotherapy method used for the treatment of cancer. It involves the removal of the T cells from the patient’s blood before reinsertion after incorporating genetically altered mechanism. The patient’s T-cells are used to develop the CAR T cell therapy for the individual. Furthermore, the therapy does not require the patient to visit the hospital frequently. This factor increases the preference for CAR T cell therapy among patients.

  2. Market Trends, Drivers, Restraints, and Opportunities: •High competition among the players operating in the global CAR T cell therapy market. This is projected to further intensify owing to the commercial launches of several products of by 2022. •Radiation and chemotherapy are currently the only treatments available in most parts of the world for the treatment of cancer. The introduction of CAR T cell therapy is expected to create numerous opportunities in the market in the coming years. •Rising research for the adoption of CAR T cell in other therapeutics treatments is expected to boost the market further. •Academic institutes, market participants, and private research firms are investing heavily in extensive research and development activities for the development of immuno-oncology. This, in turn, is projected to drive the growth of the market. Request for Free Sample: https://dataintelo.com/request- sample/?reportId=113143 Scope of the Report: The report on the CAR T cell therapy market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have been included in the report. Attributes Details Base year 2019 Historic data 2015–2019 Forecast period 2020–2026 North America, Asia Pacific, Europe, Latin America, and Middle East & Africa Regional scope

  3. Company share, market analysis and size, competitive landscape, growth factors and trends, and revenue forecast Report coverage CAR T Cell Therapy Market Segment Insights: The CD19 segment is expected to dominate the market during the forecast period due to rising prevalence of certain types of cancers On the basis of target antigens, the market has been categorized as CD19, CD22, and others. The human CD19 antigen is a 95 kd transmembrane glycoprotein belonging to the immunoglobulin superfamily. CD19 is classified as a type I transmembrane protein, with a single transmembrane domain, a cytoplasmic C- terminus, and extracellular N-terminus. CD19 is used to diagnose cancers that arise from B cell lymphomas, acute lymphoblastic leukemia, and chronic lymphocytic leukemia. Rising prevalence of these cancers is projected to fuel the growth of the segment during the forecast period. Increasing prevalence of diffuse large B-cell lymphoma is driving the growth of the large B-cell lymphoma segment Based on applications, the market has been divided into acute lymphoblastic leukemia and diffuse large b-cell lymphoma, and others. Diffuse large B-cell lymphoma is type of non-Hodgkin lymphoma (NHL). It accounts for nearly 22% of newly diagnosed cases in the US alone. Every year, more than 18,000 people are diagnosed with DLBCL. Surge in the prevalence of B-cell lymphoma is estimated to catapult the expansion of the segment between 2020 and 2026. North America to lead the global market In terms of regions, the global CAR T Cell therapy market has been segregated into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to lead the global market owing to the increase in the number of cancer cases in this region. The market in Asia Pacific is anticipated to expand at significant growth rate during the forecast period owing to the rapid developments in the healthcare infrastructure and disposable income.

  4. Competitive Landscape: Key players operating in the global CAR T cell therapy market include Novartis AG, Gilead Sciences Inc., Celgene Corporation, and bluebird bio Inc. These players engage in product launches, mergers & acquisitions, agreements, and partnerships to strengthen their geographical presence. Segments Covered in the Report: The global CAR T cell therapy market has been segmented on the basis of target antigens, applications, and regions. By Target Antigens •CD19 •CD22 •Others By Applications •Acute Lymphoblastic Leukemia •Diffuse Large B-Cell Lymphoma •Others By Regions •North America •Asia Pacific •Europe •Latin America •Middle East & Africa Discover More @ https://dataintelo.com

More Related